|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2001-9-4
|
|
pubmed:abstractText |
The ability to prescribe treatment based on relative risks for normal tissue injury has important implications for oncologists. In non-small-cell lung cancer, increasing the dose of radiation may improve local control and survival. Changes in plasma transforming growth factor beta (TGFbeta) levels during radiotherapy (RT) may identify patients at low risk for complications in whom higher doses of radiation could be safely delivered.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AnscherM SMS,
pubmed-author:CloughRR,
pubmed-author:CrawfordJJ,
pubmed-author:GarstJJ,
pubmed-author:HerndonJ EJE2nd,
pubmed-author:HuangHH,
pubmed-author:JirtleR LRL,
pubmed-author:MarksL BLB,
pubmed-author:MunleyMM,
pubmed-author:ShafmanT DTD,
pubmed-author:TischAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3758-65
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11533099-Adult,
pubmed-meshheading:11533099-Aged,
pubmed-meshheading:11533099-Aged, 80 and over,
pubmed-meshheading:11533099-Biological Markers,
pubmed-meshheading:11533099-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:11533099-Female,
pubmed-meshheading:11533099-Humans,
pubmed-meshheading:11533099-Lung Neoplasms,
pubmed-meshheading:11533099-Male,
pubmed-meshheading:11533099-Maximum Tolerated Dose,
pubmed-meshheading:11533099-Middle Aged,
pubmed-meshheading:11533099-Patient Selection,
pubmed-meshheading:11533099-Prospective Studies,
pubmed-meshheading:11533099-Radiation Injuries,
pubmed-meshheading:11533099-Radiotherapy, Conformal,
pubmed-meshheading:11533099-Radiotherapy Dosage,
pubmed-meshheading:11533099-Sensitivity and Specificity,
pubmed-meshheading:11533099-Survival Rate,
pubmed-meshheading:11533099-Transforming Growth Factor beta
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. anscher@radonc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
